CVRX CVRx, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1235912 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.8%
TTM net income YoY-2.4%
TTM EPS YoY-0.5%
Revenue 3-yr CAGR19.7%
Net income 3-yr CAGR—
Margins
Gross margin86.9%
Operating margin-81.9%
Net margin-88.3%
FCF margin-69.7%
EBITDA margin-80.6%
Returns
ROE-172.2%
ROA-53.5%
ROIC (approx.)-299.0%
Asset turnover0.61x
Leverage & solvency
Liabilities / assets84.2%
Debt / equity4.24x
Current ratio6.80x
Interest coverage-8.03x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $56.65M | $51.29M |
| Cost of revenue | $8.31M | $8.33M |
| Gross profit | $48.34M | $42.96M |
| R&D expense | $11.13M | $11.13M |
| SG&A expense | $88.47M | $91.32M |
| Operating income | -$51.27M | -$59.49M |
| Interest expense | $5.83M | $4.40M |
| Pretax income | -$53.32M | -$59.91M |
| Income tax | -$18,000 | $55,000 |
| Net income | -$53.31M | -$59.97M |
| EBITDA | -$50.51M | -$58.87M |
| EPS (basic) | -2.04 | -2.65 |
| EPS (diluted) | -2.04 | -2.65 |
| Weighted avg. shares (diluted) | 26.08M | 22.60M |
| Balance sheet | ||
| Cash & equivalents | $75.71M | $105.93M |
| Receivables | $10.66M | $9.27M |
| Inventory | $12.21M | $12.11M |
| Current assets | $101.65M | $129.81M |
| PP&E, net | $2.24M | $2.50M |
| Total assets | $104.79M | $133.41M |
| Current liabilities | $13.32M | $10.76M |
| Long-term debt | $49.51M | $49.27M |
| Total debt | $49.51M | $49.27M |
| Total liabilities | $65.47M | $62.36M |
| Shareholders' equity | $39.32M | $71.06M |
| Net debt | -$26.19M | -$56.66M |
| Shares outstanding | 26.31M | 25.32M |
| Cash flow statement | ||
| Operating cash flow | -$40.17M | -$39.14M |
| Capital expenditure | $580,000 | $1.36M |
| Free cash flow | -$40.75M | -$40.51M |
| Investing cash flow | -$580,000 | -$1.36M |
| Financing cash flow | $10.52M | $55.87M |
| Depreciation & amortization | $756,000 | $619,000 |
| Stock-based compensation | $11.05M | $19.05M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.